Catching a Glimpse of Gut Microbiome-Drug Interactions: What Clinical Pharmacologists Need to Know

Co-Chairs: Sook Wah Yee, PhD & Eugene Chen, PhD



Clinical Pharmacology

The microbial pharmacists within us: a <u>metagenomic</u> view of xenobiotic metabolism

Is It Time for a <u>Metagenomic</u> Basis of Therapeutics?

Peter Spanogiannopoulos, Elizabeth N. Bess, Rachel N. Carmody and Peter J. Turnbaugh

Henry J. Haiser and Peter J. Turnbaugh*

<u>Microbiota–drug interactions</u>: Impact on metabolism and efficacy of therapeutics

Ellen M. Wilkinson^{a,b,1}, Zehra Esra Ilhan^a, Melissa M. Herbst-Kralovetz^{a,c,*}

How to Determine the Role of the Microbiome in Drug Disposition

Jordan E. Bisanz, Peter Spanogiannopoulos, Lindsey M. Pieper, Annamarie E. Bustion, and Deter J. Turnbaugh

Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of <u>drug-microbiome</u> interactions

Ramy K. Aziz, Shaimaa M. Hegazy, Reem Yasser, Mariam R. Rizkallah & Marwa T. ElRakaiby

Siri, What Should I Eat?

Reiner Jumpertz von Schwartzenberg^{1,2} and Peter J. Turnbaugh^{1,*}

Objectives

 Describe the mechanisms by which gut microbes may alter drug absorption and elimination.

 Give at least two examples of bacteroides responsible for modulating drug efficacy and toxicity and two examples of drugs that will alter gut microbiome.



Merican Society for Clinical Pharmacology & Therapeutics







Libusha Kelly, Ph.D., Albert Einstein College of Medicine

@microbegrrl

Kathy Giacomini, Ph.D., University of California San Francisco, CA @pgrnhub @ucstanfordcersi

Lei Zhang, Ph.D., Silver Spring, MD

Take Home Messages

Take Home Messages



- Gut microbiome can activate or inactivate drug. This can be due to variability in composition of the gut microbiome.
 - E.g. irinotecan





- There is no known bioequivalence (BE) study failure that are attributed to gut microbiome interactions.
- Drug developers need to understand gut microbiome interaction to ensure their products pass BE study.

- Excipients can inhibit BCRP and OATP2B1 and that can affect drug absorption/bioavailability.
- Gut microbiome can reduce azo compound that can mitigate the inhibitory effect.